Abbasi Salah Y, Taani Hani El, Saad Adnan, Badheeb Ahmed, Addasi Ala'
Medical Oncology Department King Hussein Cancer Center Amman, Jordan.
Gastrointest Cancer Res. 2011 Jul;4(4):122-7.
WE REPORT THE EPIDEMIOLOGIC FEATURES AND THE TREATMENT EXPERIENCE OF ADVANCED GASTRIC CANCER (GC) AT KING HUSSEIN CANCER CENTER (KHCC) IN JORDAN, AND WE RETROSPECTIVELY COMPARE OUTCOMES OF TWO DIFFERENT REGIMENS: DCF (docetaxel/cisplatin/5-fluorouracil) vs. ECF (epirubicin/cisplatin/5-fluorouracil).
Charts of 162 patients with inoperable GC treated between January 2004 and December 2008 were reviewed. A total 143 patients received chemotherapy (ECF = 113; DCF = 30). Choice of regimen was changed from ECF to DCF on January 2008 according to KHCC guidelines.
The median patient age was 59 years, with a male:female ratio of 1.8:1. Lymph nodes (67.9%) and liver (49.4%) were the most common sites of metastasis. Primary disease site was stomach in 78.4%, gastroesophageal junction in 16.7%, lower esophagus in 4.9%. Poorly differentiated histology was predominant (46.9%). Anemia (53.7%), pain (48.1%), and reflux (44.4%) were the most common presenting symptoms. Helicobacter pylori infection was present in 79%. Average time between initial symptom and diagnosis was 6.0 months. The overall response rate (ORR) was 59.3% with DCF and 32.6% with ECF (P = .01). Time to tumor progression (TTP) was 6.9 months with DCF and 5.9 months with ECF (P = .005). Median survival was 11.0 months with DCF and 10.2 months with ECF (P = .17).
Some epidemiologic features of GC in Jordan mimic those of high-risk areas. Our outcomes of chemotherapy are comparable to internationally reported data and suggest superiority of DCF over ECF in terms of ORR and TTP.
我们报告了约旦侯赛因国王癌症中心（KHCC）晚期胃癌（GC）的流行病学特征及治疗经验，并回顾性比较了两种不同方案的治疗结果：多西他赛/顺铂/5-氟尿嘧啶（DCF）方案与表柔比星/顺铂/5-氟尿嘧啶（ECF）方案。
回顾了2004年1月至2008年12月期间接受治疗的162例无法手术的GC患者的病历。共有143例患者接受了化疗（ECF方案 = 113例；DCF方案 = 30例）。根据KHCC指南，2008年1月起化疗方案的选择从ECF改为DCF。
患者中位年龄为59岁，男女比例为1.8:1。淋巴结转移（67.9%）和肝转移（49.4%）是最常见的转移部位。原发疾病部位在胃的占78.4%，在胃食管交界处的占16.7%，在食管下段的占4.9%。组织学分级差的占多数（46.9%）。贫血（53.7%）、疼痛（48.1%）和反流（44.4%）是最常见的首发症状。幽门螺杆菌感染率为79%。初始症状至诊断的平均时间为6.0个月。DCF方案的总缓解率（ORR）为59.3%，ECF方案为32.6%（P = 0.01）。DCF方案的肿瘤进展时间（TTP）为6.9个月，ECF方案为5.9个月（P = 0.005）。DCF方案的中位生存期为11.0个月，ECF方案为10.2个月（P = 0.17）。
约旦GC的一些流行病学特征与高危地区相似。我们的化疗结果与国际报告的数据相当，并且表明DCF方案在ORR和TTP方面优于ECF方案。
